Trevena to Present at the 2016 Wedbush Pacgrow Healthcare Conference
August 10 2016 - 7:00AM
Business Wire
Trevena, Inc. (NASDAQ: TRVN), a clinical-stage biopharmaceutical
company focused on the discovery and development of biased ligands
targeting G protein coupled receptors, today announced that the
company will be webcasting its corporate presentation at the 2016
Wedbush Pacgrow Healthcare Conference on Tuesday, August 16, 2016
at 2:30 p.m. EDT in New York.
To access the live audio webcast of the presentation, please
visit the “Investors” section of the company’s website at
www.trevena.com. Following the conclusion of the presentation, the
webcast will be archived for 30 days.
About Trevena
Trevena, Inc. is a clinical stage biopharmaceutical company that
discovers, develops, and intends to commercialize therapeutics that
use a novel approach to target G protein coupled receptors, or
GPCRs. Oliceridine (TRV130), Trevena’s lead product candidate, is
the first pain program granted Breakthrough Therapy designation by
the U.S. Food & Drug Administration and is in Phase 3
development for intravenous treatment of moderate to severe
post-operative acute pain. In Phase 2b, intravenous oliceridine
demonstrated rapid and powerful analgesic efficacy with reduced
frequency of opioid-related adverse events including nausea,
vomiting, and hypoventilation compared to intravenous morphine,
thus offering a promising safety and tolerability profile compared
to conventional opioid analgesics while providing powerful pain
relief to patients.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160810005175/en/
Trevena, Inc.Jonathan Violin, Ph.D.Sr. Director of Investor
Relations610-354-8840 x231jviolin@trevenainc.com
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Apr 2023 to Apr 2024